Immunovant, Inc.
IMVT
$22.71
$0.693.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.19% | 38.37% | 36.10% | 49.69% | 33.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.84% | 34.94% | 40.73% | 85.70% | 87.29% |
| Operating Income | -13.84% | -34.94% | -40.73% | -85.70% | -87.29% |
| Income Before Tax | -15.47% | -37.47% | -40.99% | -115.37% | -87.33% |
| Income Tax Expenses | 661.54% | 1,085.71% | 151.29% | 240.74% | -82.82% |
| Earnings from Continuing Operations | -15.93% | -38.40% | -41.33% | -116.11% | -86.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.93% | -38.40% | -41.33% | -116.11% | -86.01% |
| EBIT | -13.84% | -34.94% | -40.73% | -85.70% | -87.29% |
| EBITDA | -13.84% | -34.94% | -40.71% | -85.71% | -87.31% |
| EPS Basic | 2.21% | -18.32% | -23.20% | -112.56% | -66.55% |
| Normalized Basic EPS | 2.60% | -17.53% | -22.89% | -111.89% | -67.74% |
| EPS Diluted | 2.21% | -18.32% | -23.20% | -112.56% | -66.55% |
| Normalized Diluted EPS | 2.60% | -17.53% | -22.89% | -111.89% | -67.74% |
| Average Basic Shares Outstanding | 18.55% | 16.97% | 14.71% | 1.66% | 11.68% |
| Average Diluted Shares Outstanding | 18.55% | 16.97% | 14.71% | 1.66% | 11.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |